Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...
Pharmabiz

EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML

EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML: Basel Monday, October 20, 2025, 11:00 Hrs [IST] Novartis announced t ...

CML Treatment Goals Are Evolving: Why Deeper Responses and Quality of Life Matter More Than Ever

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...
Targeted Oncology

FDA Issues CRL to NDA for Dasynoc in CML and ALL

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...
The Pharma Letter

Xspray’s Dasynoc NDA thwarted by manufacturing issues

Swedish oncology specialist Xspray Pharma has received a complete response letter (CRL) from the US Food and Drug ...
finanzen.at

Press Release: Novartis Scemblix(R) receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, ...

Novartis Pharma AG: Novartis Scemblix receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix i ...